A Phase I Trial of UCN-01 and Prednisone in Patients With Refractory Solid Tumors and Lymphomas

PURPOSE: UCN-01 potently inhibits protein kinase C, phosphatidylinositide-dependent kinase-1, and checkpoint kinase 1, which are involved in regulating cell cycle progression. We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kummar, Shivaani, Gutierrez, Martin E., Gardner, Erin R., Figg, William, Melillo, Giovanni, Dancey, Janet, Sausville, Edward A., Conley, Barbara A., Murgo, Anthony J., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2854012/
https://ncbi.nlm.nih.gov/pubmed/19894051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-009-1154-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados